Market Cap 414.53M
Revenue (ttm) 23.61M
Net Income (ttm) -105.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -446.89%
Debt to Equity Ratio 1.50
Volume 320,376
Avg Vol 440,874
Day's Range N/A - N/A
Shares Out 54.12M
Stochastic %K 21%
Beta 1.94
Analysts Strong Sell
Price Target $22.29

Latest News on ZVRA

Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 3 days ago

Zevra Therapeutics Files Preliminary Proxy


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 5 weeks ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 4 months ago

Zevra Therapeutics Announces Organizational Changes


Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:12 AM EST - 5 months ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript


US FDA approves Zevra's genetic disorder treatment

Sep 20, 2024, 10:14 AM EDT - 7 months ago

US FDA approves Zevra's genetic disorder treatment


Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 9:45 PM EDT - 8 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript


Zevra Therapeutics Expands Executive Leadership Team

Jun 25, 2024, 7:30 AM EDT - 10 months ago

Zevra Therapeutics Expands Executive Leadership Team


Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:53 PM EDT - 11 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript